NCT06536101View on ClinicalTrials.gov

The Purpose of the Study is to Evaluate the Safety, Tolerability and Pharmacokinetics of Single-ascending and Multiple-ascending Doses of GIM-407

PHASE1CompletedINTERVENTIONAL

Enrollment

48

Participants

Timeline

Start Date

September 2, 2024

Primary Completion Date

April 5, 2025

Study Completion Date

April 5, 2025

Conditions

Healthy Volunteers

Interventions

DRUG

GIM-407

GIM-407 oral dose

DRUG

Placebo

Matching placebo oral dose

Trial Locations (1)

3004

Nucleus Network Pty Ltd, Melbourne

Sponsors

Lead Sponsor

Georgiamune Inc

All Listed Sponsors

lead

Georgiamune Inc

INDUSTRY

NCT06536101 - The Purpose of the Study is to Evaluate the Safety, Tolerability and Pharmacokinetics of Single-ascending and Multiple-ascending Doses of GIM-407 | Biotech Hunter | Biotech Hunter